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that adjunctive treatment with aripiprazole provides health beneﬁts compared to 
quetiapine and olanzapine in patients with MDD that fail to respond to conventional 
antidepressants. With country speciﬁc cost-data, this model is also suited to assess the 
cost-effectiveness of different adjunctive strategies in MDD in different countries.
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ANTIPSYCHOTICS IN REDUCING RELAPSES IN ADULT 
SCHIZOPHRENIA PATIENTS: A SYSTEMATIC REVIEW AND MIXED 
TREATMENT COMPARISON ANALYSIS
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OBJECTIVES: To compare injectable and oral atypical antipsychotics in reducing 
relapses in adult schizophrenia patients. METHODS: A systematic review of literature 
was conducted in MEDLINE and EMBASE (January 1995-August 2009) to identify 
randomized controlled trials and comparative open-label studies of atypical antipsy-
chotics performed on adult schizophrenia outpatients. Proceedings of the American 
Psychiatric Association Conference from 2006 to 2009 and bibliographies of identiﬁed 
studies and relevant reviews were also searched. Included studies had to have a clear 
deﬁnition of relapse (e.g. hospitalization or return to symptomatic condition), and a 
minimum follow-up period of 6 months. Comparators included atypical antipsychot-
ics, typical antipsychotics, or placebo. Data extraction was validated by a second 
reviewer. A Bayesian mixed treatment comparison (MTC), enabling indirect compari-
sons of interventions while respecting randomization, was performed on the rate of 
relapse assuming random study effects. RESULTS: Ten articles were identiﬁed and 
included in the systematic review and MTC. The odds ratio (OR) [95% credible 
interval (CI)] of relapse relative to placebo ranged from 0.13 [0.04, 0.47] (oral 
risperidone) to 0.20 [0.03, 1.19] (aripiprazole) among oral atypical agents, and 0.29 
[0.07, 1.12] for typical agent haloperidol. The OR [95% CI] of relapse of injectible 
risperidone relative to oral formulations of atypicals ranged from 0.28 [0.05, 1.24] 
(aripiprazole) to 0.41 [0.12, 1.01] (olanzapine). Injectable risperidone had lower odds 
of relapse than oral risperidone, olanzapine, quetiapine, aripiprazole, combination 
therapy, haloperidol, and placebo with probabilities > 95% and quetiapine XR, clo-
zapine, and ziprasidone with probabilities of 85%, 90%, and 93%, respectively. 
Findings were robust to varying trial durations and responder deﬁnitions. CONCLU-
SIONS: Oral formulations of various atypical antipsychotics, as well as typical halo-
peridol, offer similar beneﬁts over placebo in reducing relapse rates. Statistical and 
clinically important differences in relapse rates exist between oral and injectable for-
mulations of atypicals in favor of injectable risperidone.
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OBJECTIVES: There are four FDA-approved alcoholism medications: disulﬁram, 
naltrexone, acamprosate, and extended-release naltrexone (XR-NTX). This study used 
observational data to evaluate the utilization and cost outcomes of insured patients 
treated with alcohol medications or no medication. METHODS: Data were from 
Thomson Reuter’s MarketScan Commercial insurance claims database which contains 
information from millions of enrollees annually. Outcomes were measured six months 
after index and included medication possession ratio (MPR), detoxiﬁcation admissions 
and days, alcohol-related admissions and days, ED visits, psychiatric and substance 
abuse outpatient visits and charges for detoxiﬁcation and alcohol-related inpatient 
stays. Two sets of analyses were conducted: 1) Persons with an alcohol use disorder 
and no use of any alcohol medication (n = 4,047) were compared to persons with an 
alcohol use disorder and use of any of the four medications (n = 4,730). The samples 
were propensity-score matched on demographics, clinical characteristics and prior use 
of alcohol and psychiatric services, and 2) The four medications were compared 
(XR-NTX n = 275; naltrexone n = 2064 acamprosate n = 5068; disulﬁram n = 2076) 
using inverse probability weighting. RESULTS: The probability of any detoxiﬁcation 
admission, alcohol-related admission, and ED visit and a substance abuse or psychi-
atric visit was signiﬁcantly higher among no medication users than medications users. 
XR-naltrexone users had a signiﬁcantly higher MPR than acamprosate users. Patients 
using any medication had fewer detoxiﬁcation days and alcoholism-related inpatient 
days. Among medication users, XR-NTX was associated with signiﬁcantly lower 
detoxiﬁcation costs (per 1000 patients over 6 months) versus oral naltrexone, disul-
ﬁram and acamprosate (Detox: $0.60-million vs. $1.48-million, $1.08-million, $1.40-
million; respectively; P < 0.01 for XR-NTX vs. naltrexone and acamprosate). 
CONCLUSIONS: Individuals receiving alcoholism medications had signiﬁcantly and 
substantially lower detoxiﬁcation and hospitalization utilization rates than similar 
patients who received no medication. Of the approved medications, XR-TX had lower 
costs for detoxiﬁcation and alcoholism hospitalization days.
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OBJECTIVES: Treatment discontinuation has been increasingly used as a quantiﬁable 
tool for measuring the overall effectiveness of antipsychotic medications, including 
efﬁcacy, safety, and tolerability of a drug. While results have been inconsistent, several 
studies have found that olanzapine and other second-generation antipsychotics (SGA) 
are more effective in the treatment of schizophrenia compared to ﬁrst-generation 
antipsychotics (FGA). This meta-analysis compared time to and rate of treatment 
discontinuation of antipsychotics in schizophrenia. METHODS: Electronic search 
strategies identiﬁed all relevant papers on the topic published up to April 2009. 
Randomized controlled trials (RCTs) and observational studies that compared olan-
zapine with SGAs and/or FGAs for patients with schizophrenia were included in the 
meta-analyses. Hazard ratios (HR), Relative Risks (RR) and their associated 95% 
conﬁdence intervals (CIs) were extracted. RESULTS: There were 60 RCTs (N = 
33,360) and 27 observational studies (N = 202,591) included. The meta-analysis of 
time to discontinuation revealed that olanzapine was signiﬁcantly better as compared 
to aripiprazole, quetiapine, risperidone, ziprasidone, and perphenazine within ran-
domized trials and better than amisulpride, risperidone, haloperidol, and perphenazine 
within observational studies. Discontinuation rates in the RCTs were signiﬁcantly 
lower for olanzapine compared to all antipsychotics except for clozapine. In the 
observational studies, olanzapine was more effective than amisulpride and haloperi-
dol, and less effective than clozapine. Subgroup analysis indicated that industry spon-
sorship (Lilly vs. other sources) and olanzapine dosages did not affect the results, 
except for observational studies published by companies other than Lilly which found 
olanzapine to be more favorable compared to FGAs). CONCLUSIONS: In both 
randomized trials and observational studies, time to and rates of discontinuation, 
which are overall indices of effectiveness, olanzapine was better than most SGAs and 
FGAs, except for clozapine.
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OBJECTIVES: This study aimed to identify schizophrenia patients who experience 
favorable outcomes over a 3-year period and determine baseline predictors of favor-
able long-term outcomes. METHODS: We used data of a 3-year prospective, obser-
vational study of individuals treated for schizophrenia in the United States (US-SCAP; 
N = 2327). A hierarchical cluster analysis was performed to group patients, using 
baseline clinical, functional, and resource utilization measures. Clinical status was 
based on symptom severity. Functional level reﬂected patient-reported productivity 
and occupational role functioning. Resource utilization of psychiatric hospitalization 
and emergency services was systematically abstracted from medical records. A patient 
was classiﬁed as having a favorable long term outcome if their outcome values had 
the closest distance to the deﬁned “best baseline cluster” at each point over the 3-year 
follow-up; stepwise logistic regression was used to determine baseline predictors. 
RESULTS: Of 1604 patients with sufﬁcient data to assess 3-year outcomes, only 191 
(12%) experienced favorable outcomes. Overall, 5 distinct outcome clusters were 
identiﬁed, ranging from best to worst. The baseline predictors of the most favorable 
outcomes sustained over the 3-year period included better quality of life, more daily 
activities, patient-reported clearer thinking, less severe positive symptoms, lower AIMS 
score, higher level of global functioning, being employed, not having health insurance, 
being female, and not having help with shopping, leisure, or social activities. CON-
CLUSIONS: This study identiﬁed 5 distinct clusters of patients with schizophrenia 
based on their baseline clinical, functional, and resource utilization factors. Current 
ﬁndings suggest that clinicians could make early projections of long-term outcome, 
thus enabling early tailored therapeutic interventions that could enhance patient’s 
likelihood of achieving more favorable long-term outcomes.
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OBJECTIVES: Augmentation with atypical antipsychotics are effective in treating 
patients suffering from major depressive disorder (MDD) and that respond insufﬁ-
ciently to conventional antidepressants. Direct head-to-head trials comparing these 
agents are lacking. An indirect comparison was conducted to assess the comparative 
efﬁcacy and safety of augmentation with atypical antipsychotics in MDD. METHODS: 
A systematic literature search was conducted of Medline/PubMed (1966-September 
2009). Eligible trials enrolled patients diagnosed with unipolar major depressive dis-
order with resistance to at least one prior antidepressant. Trials had to be double-blind 
placebo controlled assessing the efﬁcacy and/or safety of augmentation therapy with 
aripiprazole, quetiapine, or olanzapine during an acute depressive episode. Response 
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rates, remission rates and discontinuation rates due to adverse events were extracted 
and compared in a Bayesian meta-analysis. RESULTS: Three aripiprazole, 2 quetiap-
ine and ﬁve olanzapine trials were identiﬁed together reporting on 2979 patients. 
Aripiprazole augmentation showed numerically higher efﬁcacy rates compared to 
quetiapine and olanzapine. Response odds ratios (95%CI) compared to quetiapine 
and olanzapine were 1.34(0.82–2.06) and 1.52(1.00–2.19) respectively. Remission 
odds ratios compared to quetiapine and olanzapine were 1.3(0.78–2.07) and 
1.26(0.77–1.92) respectively. Aripiprazole augmentation showed numerically lower 
discontinuation rates due to adverse events compared to quetiapine and olanzapine 
(OR = 0.99(0.24–2.62) and 0.77(0.23–1.89)). CONCLUSIONS: Amongst augmenta-
tion treatments with atypical antipsychotics in MDD, aripiprazole shows a tendency 
towards higher efﬁcacy rates and lower discontinuation rates due to adverse events 
compared to quetiapine and olanzapine. More direct head-to-head trials are needed 
to assess the comparative efﬁcacy and safety of adjunctive antipsychotics in MDD.
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OBJECTIVES: This study aimed to determine distinct subgroups of schizophrenia 
patients based on their illness severity at baseline and characterize those who were 
most improved and those who worsened the most. METHODS: We used data from 
a large 3-year prospective, multi-site, observational non-interventional study of indi-
viduals treated for schizophrenia in the United States (US-SCAP). A hierarchical cluster 
analysis was performed to group the patients, using baseline clinical, functional, and 
resource utilization measures. Improvement of outcome was determined based on the 
distance from the deﬁned “worst baseline cluster” for each post-baseline measure. A 
trajectory analysis was used to group patients by improvement of outcome over the 
3-year study. RESULTS: Almost all participants (99% or 872/880) with 3-year data 
were found in a single outcomes trajectory, characterized by minimal changes from 
baseline cluster over the 3-year study period. Approximately one-fourth of individuals 
moved to a better outcome cluster while about 17% moved to a worse outcome cluster 
at each year. Only 4% of patients moved from the worst/next to worst cluster to the 
best/next to best cluster and 16.6% moved from the best/next to best cluster to the 
worst/next to worst cluster. Most improved patients were more likely than all other 
patients to have case management, to live in a supervised housing arrangement, and 
get assistance with securing social services and beneﬁts. CONCLUSIONS: The long-
term outcome trajectory for almost all schizophrenia patients in this 3-year naturalistic 
observational study was stable, devoid of change from the baseline cluster. Only a 
very small subgroup of patients experienced marked improvements, and they were 
more likely to be engaged in psychosocial rehabilitation. Although current ﬁndings 
may afﬁrm the value of psychosocial rehabilitation, results highlight the need to 
improve the relatively stagnant long-term illness trajectory of almost all chronically 
ill patients with schizophrenia.
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OBJECTIVES: Approved treatments for attention-deﬁcit/hyperactivity disorder 
(ADHD) in Canada comprise short-acting (SA) and long-acting (LA) stimulants and 
a LA nonstimulant medication. The objective of this study was to elucidate different 
drug treatment patterns to treat ADHD in Canada. METHODS: A retrospective 
prescription claims analysis of a random sample of 15,838 ADHD patients from the 
Quebec provincial health plan (RAMQ) database was conducted. Any patient with 
≥1 physician claim with an ADHD diagnosis and a claim for a treatment approved 
for ADHD from July 2004 to June 2009 was considered. RESULTS: The mean age 
of the study sample was 14.0 years (SD = 8); 72.6% of the sample were males. There 
were a total of 416,646 ADHD prescriptions during the 5-year study period. As a 
proportion of total prescriptions, use of SA medications declined from 72.83% in 
2004 to 26.38% in 2009, while use of stimulant and nonstimulant LA medications 
increased from 27.17% to 73.62% over the same period. Approximately half of the 
patients used both SA and LA medications either concomitantly or subsequently while 
approximately 30% used only SA and 19% used only LA. Among those patients who 
used both types of formulations, switching from SA to LA was the most frequent 
(27.9%) treatment pattern. A greater proportion of patients (6.4%) on LA methyl-
phenidates required augmentation with SA medications when compared with those 
on LA amphetamines (1.9%; p < 0.01). CONCLUSIONS: Results of this RAMQ 
database analysis illustrate that over time, patients shifted from the use of SA stimu-
lants to formulations that provide all-day coverage. Switching from SA to LA medica-
tions and augmentation of LA medications with SA medication are common treatment 
patterns observed in the management of ADHD with implications for patient care and 
the efﬁcient use of health care resources. Supported by funding from Shire Develop-
ment Inc.
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TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
Walczak J, Małysiak S, Rowin´ska M
Arcana Institute, Cracow, Poland
OBJECTIVES: The purpose of the review was to evaluate the efﬁcacy and safety of 
escitalopram compared with sertraline and venlafaxine in treatment of major depres-
sive disorder (MDD). METHODS: The analysis was performed in accordance with 
the rules of systematic review, based on Cochrane Collaboration guidelines and recom-
mendations of Health Technology Assessment Agency in Poland (AOTM). RESULTS: 
In this report there were two subanalyses conducted, evaluating the efﬁcacy and safety 
of escitalopram in comparison with sertraline and venlafaxine, both consisted of two 
multicenter, parallel-group, double-blinded, randomized clinical trials. In both com-
parisons efﬁcacy was evaluated, based on the mean changes in MADRS, HAM-D, 
CGI-S, CES-D, HAM-A and CGI-I grading scales, as well as safety analysis was 
performed. Period of eight weeks treatment with escitalopram and sertraline as well 
as venlafaxine resulted in decrease in number of MDD symptoms and quality of life 
improvement. Over 50% decrease in number of major depression symptoms in 
MADRS and HAM-D grading scales compared to baseline indicates high clinical 
relevance of obtained results, even though statistical signiﬁcance was not reached. 
Safety analysis showed similar safety proﬁles of all drugs taken into account. There 
were no statistical differences between populations in any of primary endpoints, except 
for withdrawals from the study due to adverse events in comparison of escitalopram 
vs venlafaxine favoring escitalopram. CONCLUSIONS: Escitalopram seems to be 
equally efﬁcient and safe drug as sertraline and venlafaxine in treatment of patients 
with MDD. The clinical-effectiveness analysis ascertained equivalence of efﬁcacy and 
similarity of safety proﬁle of escitalopram in comparison with sertraline and venla-
faxine in therapy of patients with MDD.
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OBJECTIVES: In pharmaceutical outcomes research using health care claims data-
bases, periods during which patients are hospitalized have constituted “black holes”, 
as these databases do not contain any information on pharmacotherapy received in 
hospital. While admission-level databases provide such information, they lack infor-
mation on pharmacotherapy received outside of hospital. Recently, it has become 
possible to link these two types of databases. In this study, we explored their potential 
value to outcomes research, focusing attention on second-generation antipsychotic 
(SGA) treatment before, during, and after hospitalization for schizophrenia. 
METHODS: Using a linked inpatient/outpatient database, we identiﬁed all adults with 
≥1 admissions for schizophrenia between January 1, 2001 and September 30, 2008. 
Focusing on each patient’s ﬁrst admission, we compiled all health care claims during 
the 6-month periods preceding and following hospitalization. As our interest was in 
the use of SGAs, our scope was limited to patients with evidence of receipt of oral 
ziprasidone, aripiprazole, or quetiapine (“study agents”) immediately preceding hos-
pital discharge. We then examined receipt of these agents during the 6-month periods 
preceding hospitalization and following hospital discharge based on outpatient phar-
macy claims; receipt of study agents in hospital was examined using admission-level 
data. Adherence with study agents following hospital discharge was assessed using 
proportion of days covered (PDC); patients were deemed nonadherent if PDC fell 
below 80%. RESULTS: A total of 43 patients were identiﬁed who met all study entry 
criteria. Twenty-four patients (56%) had evidence of receipt of a study agent in the 
period preceding hospitalization. While all patients had evidence of receipt of study 
agents following hospital discharge, only 12% were adherent at 6 months. CONCLU-
SIONS: Linked inpatient/outpatient databases are a promising avenue for future 
pharmaceutical outcomes research, as they may greatly expand understanding of the 
complete chronology of pharmacotherapy–and associated outcomes–for many disease 
conditions.
PMH21
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OBJECTIVES: To examine prevalence and predictors of anticholinergic medication 
use in elderly nursing home residents with dementia. METHODS: The study evaluated 
anticholinergic medication use in elderly (>= 65 years) nursing home residents using 
the 2004 National Nursing Home Survey (NNHS). Anticholinergic Drug Scale was 
used to classify medications as Level 1, Level 2 or Level 3 in order of their increasing 
anticholinergic activity. Descriptive weighted analysis was used to determine the 
prevalence of anticholinergic medication use in elderly dementia patients. Multinomial 
logistic regression within the conceptual framework of Andersen Behavioral Model 
(ABM) was used to examine the predictors associated with each level of anticholinergic 
medication use as well as concurrent use of anticholinergic medications belonging to 
two or more levels. RESULTS: According to the NNHS, 0.51 million (95% CI-0.49–
0.53) or 73.62% (72.23–75.00) of the elderly patients with dementia used anticho-
